VistaGen Therapeutics Inc (VTGN)       0.8721  -0.01 (-0.9%)

0.8721  -0.01 (-0.9%)

US92840H2022 - Common Stock - After market: 0.87 0 (-0.24%)

News Image
a month ago - VistaGen Therapeutics, Inc.

VistaGen to Participate in Upcoming June Investor Conferences

News Image
2 months ago - InvestorPlace

7 Cheap Biotech Stocks to Buy Now

These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.

News Image
2 months ago - VistaGen Therapeutics, Inc.

VistaGen Appoints Reid Adler as Chief Legal Officer

News Image
3 months ago - VistaGen Therapeutics, Inc.

VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage,...

News Image
5 months ago - VistaGen Therapeutics, Inc.

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to...

News Image
5 months ago - VistaGen Therapeutics, Inc.

VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to...

News Image
8 months ago - Zacks Investment Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News Image
8 months ago - VistaGen Therapeutics, Inc.

VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update

PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan ...

News Image
8 months ago - Zacks Investment Research

Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know

VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.